logo
Heart attack deaths have plummeted in US, but new cardiovascular threats emerge

Heart attack deaths have plummeted in US, but new cardiovascular threats emerge

Fox News2 days ago

Print Close
By Melissa Rudy
Published June 26, 2025
Heart attack deaths have plummeted in recent years — but other types of cardiovascular disease still pose a major threat.
A new study by the American Heart Association (AHA) found that overall heart disease-related death rates have declined by 66%, and heart attack deaths have dropped by almost 90%.
While heart attacks are no longer the most fatal form of heart disease, there have been increases in other types — heart failure, arrhythmias (irregular heartbeats) and hypertensive heart disease (long-term high blood pressure).
CANNABIS USE RAISES RISK OF HEART ATTACK AND STROKE MORE THAN COCAINE, OTHER DRUGS, MAJOR REVIEW SUGGESTS
The findings were published in the peer-reviewed Journal of the American Heart Association.
In the study, researchers analyzed more than 50 years of data from the U.S. Centers for Disease Control and Prevention (CDC), focusing on heart disease deaths among adults aged 25 and older.
In 1970, heart attacks — also known as ischemic heart disease — represented more than half (54%) of all heart disease deaths, the study found.
As of 2022, only 29% of heart disease deaths were caused by heart attacks.
Other types of heart disease deaths — such as heart failure, hypertensive heart disease and arrhythmia — have risen during that timeframe, however.
EXPERIMENTAL CHOLESTEROL PILL CUTS HEART ATTACK RISK WITH 'CONVENIENT' ONCE-DAILY DOSE
In 2022, these other types were responsible for 47% of heart disease deaths, up from just 9% in 1970, the study found.
"This distribution shift in the types of heart disease people were dying from the most was very interesting to us," said the study's first author, Sara King, M.D., a second-year internal medicine resident in the department of medicine at Stanford School of Medicine in Stanford, California, in the release.
"This evolution over the past 50 years reflects incredible successes in the way heart attacks and other types of ischemic heart disease are managed," she went on.
"However, the substantial increase in deaths from other types of heart conditions, including heart failure and arrhythmias, poses emerging challenges the medical community must address."
"The increase in other types of heart disease leading to death has offset the wins from deaths from heart attacks declining."
Arrhythmias, or irregular heartbeats, happen when electrical impulses to the heart are too fast, slow or erratic, according to the AHA. One common example of an arrhythmia is atrial fibrillation (AFib), which begins in the upper chambers of the heart.
Heart failure is defined as a "chronic condition where the heart is unable to pump enough blood to meet the body's needs for blood and oxygen."
Hypertensive heart disease describes damage to the heart caused by long-term, unaddressed high blood pressure, the AHA stated.
Sadiya S. Khan, MD, a cardiologist and associate professor at Northwestern University in Chicago, was not involved in the study but commented on the "important analysis."
"Fortunately, this study suggests important progress in a preventable cause of death — heart attacks," she told Fox News Digital.
STANFORD RESEARCHERS DEVELOP 'GAME-CHANGING' STROKE TREATMENT THAT DOUBLES EFFECTIVENESS
"Unfortunately, it suggests that there is a smoldering crisis of other types of heart disease deaths that may be in part related to heart attacks, but speak to the growing burden of obesity that results in more heart failure and arrhythmia-related deaths."
"The increase in other types of heart disease leading to death has offset the wins from deaths from heart attacks declining." Why the decrease in heart attacks?
The researchers presented several possible reasons for the decrease in heart attack deaths, primarily advancements in treatment for sudden and acute cardiac events.
"From the establishment and increased use of bystander CPR and automated external defibrillators (AEDs) to treat cardiac arrest outside the hospital setting, to the creation of systems of care that promote early recognition of and quick procedural and medical intervention to treat heart attacks, there have been great strides made in helping people survive initial acute cardiac events that were once considered a death sentence," King said in the release.
The researchers also touted several other medical advancements, including coronary artery bypass grafting, cardiac imaging and many new heart disease medications.
Healthy lifestyle modifications, such as quitting smoking, exercising regularly and managing cholesterol and blood pressure, have also contributed to the reduced heart attack deaths, the AHA report stated.
Khan added, "It is important to note that this doesn't mean the heart attack may still not have been the driver, if someone with a heart attack developed heart failure and that is now called a heart failure death." Risk factors remain
Despite the improvements, the researchers cautioned that several other heart disease risk factors — including obesity, type 2 diabetes, hypertension and physical inactivity — are still fueling cases.
Obesity in particular has risen from 15% to 40% during the study timeframe, and type 2 diabetes affects nearly half of U.S. adults, according to the report.
Increased life expectancy is another factor — as people are living longer, a larger aging population is more likely to experience various types of heart disease.
CLICK HERE TO GET THE FOX NEWS APP
"We've won major battles against heart attacks; however, the war against heart disease isn't over," King said. "We now need to tackle heart failure and other chronic conditions that affect people as they age."
"The next frontier in heart health must focus on preventing heart attacks, and also on helping people age with healthier hearts and avoiding chronic heart conditions later in life."
The AHA calculates heart health based on an individual's score for what it calls "Life's Essential 8."
Those who score high in those eight areas are, on average, six years younger biologically than their actual age.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The eight lifestyle behaviors for optimal heart health are listed below. Eat better Be more active Quit tobacco Get healthy sleep Manage weight Control cholesterol Manage blood sugar Manage blood pressure Potential limitations
The researchers pointed out several limitations of their study, including that they did not analyze data by age, sex, race, ethnicity, region or urbanization.
There could also be potential inconsistencies and "miscoding" of data over the years, they noted.
"We've won major battles against heart attacks; however, the war against heart disease isn't over."
It's also possible that the "true burden" of heart attacks is "underestimated" in the findings, according to the researchers.
"Certain conditions including heart failure, cardiomyopathy and arrhythmias — and, in particular, ventricular arrhythmias and cardiac arrest — may be overly simplistic," they wrote. "Many of these cases likely have underlying causes that cannot be precisely differentiated using current or past ICD (International Classification of Diseases) codes."
For more Health articles, visit www.foxnews.com/health
Khan pointed out that despite the decrease in direct heart attack deaths, heart disease overall is still the leading cause of mortality in the U.S., accounting for more than 900,000 deaths in 2022. Print Close
URL
https://www.foxnews.com/health/heart-attack-deaths-have-plummeted-us-new-cardiovascular-threats-emerge

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dietitian Who Lost 60 Pounds With GLP-1 Drug Reveals Foods to Avoid and Prioritize
Dietitian Who Lost 60 Pounds With GLP-1 Drug Reveals Foods to Avoid and Prioritize

Yahoo

time11 minutes ago

  • Yahoo

Dietitian Who Lost 60 Pounds With GLP-1 Drug Reveals Foods to Avoid and Prioritize

Jennifer Lynn-Pullman is a certified specialist in obesity and weight management, so she was frustrated when her own weight kept rising over the years. 'I had struggled with my weight for a long time. My whole family struggles as well, so it's very genetic,' Lynn-Pullman, 48, a registered dietitian and manager of clinical dietetics for Vida Health, tells "And of course, in your 40s with perimenopause, it doesn't get any easier.' Lynn-Pullman, who lives in suburban Philadelphia, was alarmed when her cholesterol went up for the first time two years ago and her A1C — a measure of blood sugar — was trending up. At 5 feet, 6 inches tall, she weighed 200 pounds and worried she was on track to develop Type 2 diabetes in her 50s like her parents. Her doctor prescribed Wegovy, the version of Ozempic approved for weight loss. It's part of the GLP-1 class of medications that mimic a hormone the body produces after eating to decrease appetite and help the body manage insulin production. After starting the drug in 2023, Lynn-Pullman lost 60 pounds in 10 months and has maintained that weight for more than a year. Like many patients, she experienced side effects and had to figure out which foods to avoid on a GLP-1 and how to prevent muscle loss. Here are her tips for eating on a GLP-1 based on her own experience: Lynn-Pullman had side effects for the first six months, usually when her medication dosage was increased. GLP-1 drugs slow stomach emptying, one of the reasons patients can experience uncomfortable symptoms. Nausea and vomiting are some of the most common side effects. For nausea, Lynn-Pullman prefers to use ginger gum. She also prepares easy to digest foods like a smoothie, soup and crackers that aren't too heavy for her stomach. Vomiting is usually due to eating too much or consuming high-fat foods, so she advises eating smaller meals, not eating too fast and avoiding greasy foods. 'Fat just stays in your stomach longer,' she says. 'With someone whose stomach is emptying much slower, it causes more of an upset.' Lynn-Pullman realized her vomiting episodes were caused by high-fiber muffins she was eating to help ease constipation. Once she cut them out, the problem stopped. The dietitian decided to treat herself like her bariatric surgery patients. 'I realized that because Wegovy causes such an increased level of satiety and such a long level of fullness, that it was very similar to those patients,' she says. Lynn-Pullman eats very small frequent meals she sometimes calls 'eating episodes.' She eats a higher-protein diet to help combat any muscle loss. She has protein every time she eats, consuming that food first, then fruits and vegetables. Any starchy food is last, if there's even room for it. Since liquid fills up the stomach, she suggests not drinking beverages with meals to get enough food in, then hydrating between meals. Here's her typical daily menu: Breakfast: A protein shake, cereal with fiber and ultrafiltered milk, which contains more protein than regular milk. Lunch: A turkey sandwich or salad topped with chicken. Dinner: Chicken or salmon with a vegetable. She occasionally eats rice or pasta on the side, but it fills her up too much, so she usually skips it. Snacks: An apple with peanut butter or nuts with a piece of fruit. Lynn-Pullman always loved sweets, noting she couldn't pass up a cookie or a piece of chocolate, especially in the afternoon. But after she began using Wegovy, she stopped craving sugar. 'It was the most miraculous thing,' Lynn-Pullman recalls. 'The food noise, that inner voice saying, 'Go get something sweet' — it vanished.' Today, she occasionally eats dark chocolate or might split a dessert with her husband if she goes out to dinner, but mostly skips sweets. When it comes to alcohol, she has a drink 'once in a blue moon if she goes to a party." 'The thing that I worry about is being nauseous or even feeling dehydrated the next day,' Lynn-Pullman says. 'We usually suggest that patients refrain from it just because of all of those potential side effects.' The dietitian works out three times a week, focusing on weight training to minimize muscle loss. Three months after starting Wegovy, Lynn-Pullman noticed she was cold all the time, even in the August summer heat. She began journaling her food intake and discovered she was eating only 800 calories a day, with very little protein. 'It's easy to do on a GLP-1 because you don't feel hungry and you fill up quickly,' Lynn-Pullman says. 'We worry about malnutrition, we worry about people not getting enough nutrients.' When she started eating more protein and calories, her symptoms went away quickly. That's why it's important to work with a dietitian and report symptoms like feeling cold, tired or exhausted, or noticing hair loss — potential symptoms of eating too little, Lynn-Pullman notes. This article was originally published on

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Yahoo

time21 minutes ago

  • Yahoo

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool

What to Expect From Elevance Health's Q2 2025 Earnings Report
What to Expect From Elevance Health's Q2 2025 Earnings Report

Yahoo

time31 minutes ago

  • Yahoo

What to Expect From Elevance Health's Q2 2025 Earnings Report

Valued at a market cap of $84.3 billion, Elevance Health, Inc. (ELV) is a managed healthcare company that offers a broad spectrum of health benefits and services, including medical, pharmacy, dental, vision, behavioral health, Medicare, and Medicaid plans. The Indianapolis, Indiana-based company is expected to announce its fiscal Q2 earnings for 2025 on Wednesday, Jul. 16. Prior to this event, analysts project this health insurance company to report a profit of $9.29 per share, down 8.2% from $10.12 per share in the year-ago quarter. The company has met or surpassed Wall Street's bottom-line estimates in three of the last four quarters, while missing on another occasion. Its earnings of $11.97 per share in the previous quarter aligned with the consensus estimates. Dear Nvidia Stock Fans, Watch This Event Today Closely Can Broadcom Stock Hit $400 in 2025? A $2 Billion Reason to Sell Super Micro Computer Stock Now Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For the full year, analysts expect ELV to report EPS of $34.42, up 4.2% from $33.04 in fiscal 2024. Furthermore, its EPS is expected to grow 13.8% year over year to $39.16 in fiscal 2026. Shares of Elevance Health have declined 30.2% over the past 52 weeks, considerably lagging behind both the S&P 500 Index's ($SPX) 12.1% uptick, and the Health Care Select Sector SPDR Fund's (XLV) 8.1% loss over the same time frame. On Apr. 22, shares of Elevance Health rose 2.3% as it delivered better-than-expected Q1 results. The company's operating revenue grew 15.4% year-over-year to $48.8 billion and surpassed the consensus estimates by almost 6%. Moreover, its adjusted EPS of $11.97 improved by 10.5% from the same period last year. This impressive performance was driven by higher premium yields in its health benefits segment, benefits from acquisitions completed in the past year, and strong growth in its CarelonRx product revenue. Ongoing cost management by the company further supported its profitability. Wall Street analysts are highly optimistic about ELV's stock, with a 'Strong Buy" rating overall. Among 20 analysts covering the stock, 15 recommend "Strong Buy," one suggests a 'Moderate Buy,' and four indicate 'Hold.' The mean price target for ELV is $492.94, which indicates a 32.1% potential upside from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store